IL-23 Inhibitor Effective in Crohn's Disease
Selective IL-23 inhibition has been touted to be the next great advance in the treatment of inflammatory bowel and psoriatic disease.
News
Tocilizumab Effective in PMR
Polymyalgia rheumatica (PMR) should be easy and responsive, but it can be a challenge and requires long-term steroid therapy. Problems often begin when steroid–induced side effects take their toll on a patient, especially in elderly adults.
Opioid Prescriptions in Decline
In an era of increasing fears over narcotic abuse and narcotic-related deaths, the number of opioid prescriptions in the United States is finally falling, the according to the NY Times.
TB Management Questions
The following is a compilation of several frequently asked questions regarding tuberculosis (TB) testing or treatment in patients on a TNF inhibitor (TNFi) or other biologic agents.
ORBIT Study Shows Rituximab and TNF inhibitor Equivalence
The initial choice of biologic is crucial to long-term success. Yet there are few studies evaluating head-to-head differences in some of our most popular therapies.
RheumNow Week in Review - 19 May 2016
Dr. Jack Cush reviews this week's news and research highlights from RheumNow.com.
FDA Delays Ruling on Generic Labeling
The New York Times reports that the FDA has delayed its much anticipated ruling on generics until sometime in 2017.
Musculoskeletal Complications of Hematologic Disorders Reviewed
Morais and colleagues have published an informative review of rheumatologic and musculoskeletal (MSK) disorders that may potentially befall those with benign or malignant blood disorders. It is important to be aware of these associations.
GWAS Reveals Shared Susceptibility Locus Between RA and SLE
While the phenotypes of RA and SLE are quite different, genome-wide association studies (GWAS) performed in the past have shown a genetic overlap between both.
Risk Factors for Bisphosphonate Bone Complications
Rare reports of bisphosphonate associated atypical femoral fractures (AFF) and osteonecrosis of the jaw (ONJ) have raised concerns about the chronic use of bisphosphonates. The risk of AFF and ONJ was assessed in an analysis of the Swedish national database.
Reports Call for More Gout Education
Two recent surveys show that gout patients are often uninformed, undertreated, improperly monitored and frequently stigmatized by their gout.
Cochrane Reports Moderate Evidence Favoring Biologic Add-on Therapy
Singh and coworkers have assessed the value of adding a biologic to rheumatoid arthritis (RA) patients not responding to either methotrexate (MTX) or DMARDs. The results of their netowork metanalsysis is published as a Cochrane review wherein they examined a total of 90 RCTs (73 new) with 32
